TWD 179.0
(-1.65%)
Year | Eps | Eps Growth |
---|---|---|
2023 | 4.79 TWD | -56.89% |
2022 | 11.11 TWD | 36.99% |
2021 | 8.11 TWD | 245.11% |
2020 | 2.35 TWD | -60.03% |
2019 | 5.88 TWD | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q2 | 2.29 TWD | -15.19% |
2024 Q1 | 2.70 TWD | 60.71% |
2023 Q4 | 1.68 TWD | 6.33% |
2023 FY | - TWD | -56.89% |
2023 Q3 | 1.58 TWD | 75.56% |
2023 Q2 | 0.90 TWD | 45.16% |
2023 Q1 | 0.62 TWD | -70.89% |
2022 FY | - TWD | 36.99% |
2022 Q4 | 2.13 TWD | 0.0% |
2021 FY | - TWD | 245.11% |
2020 FY | - TWD | -60.03% |
2019 FY | - TWD | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
Nang Kuang Pharmaceutical Co., Ltd. | 1.96 TWD | -144.388% |
Maxigen Biotech Inc. | 1.86 TWD | -157.527% |
SciVision Biotech Inc. | 2.66 TWD | -80.075% |
Bionime Corporation | 0.10 TWD | -4690.0% |
Pegavision Corporation | 22.83 TWD | 79.019% |